Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07633301 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
A Phase 2 study, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT07633301 is a Phase 2 study that is actively recruiting participants, run by Takeda. The registered enrollment target is 92 participants.
The verdict
NCT07633301, a Phase 2 study, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness \[EDS\]), where a person may fall asleep without warning. Narcolepsy Type 1 (NT1) is a form of the condition in which people also have sudden, unexpected muscle weakness while staying conscious (called cataplexy). The main aim of this study is to learn how safe TAK-360 is and how well adults with NT1 tolerate it. Adults who can participate in the study will have to stop taking their existing medicines for NT1 before study treatment starts. Participants may be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo during the treatment period. The placebo looks just like TAK-360 but does not have any medicine in it. After the treatment period, participants can be monitored for another 2 weeks. Participants can restart their usual NT1 treatment after study treatment ends. The participants will have to visit the clinic multiple times during this study.
Interventions
- DRUG Placebo
- DRUG TAK-360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2026-06-04 |
| Est. Completion | 2027-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07633301
The ClinicalTrials.gov registry entry for NCT07633301 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07633301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07633301 about?
NCT07633301 is a clinical study titled "A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)". Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness \[EDS\]), where a person may fall asleep without warning. Narcolepsy Type 1 (NT1) is a form of the condition in which people also have su...
What is the current status of trial NCT07633301?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2026-06-04. Estimated completion is 2027-11-28.
What interventions are being tested in trial NCT07633301?
The interventions under investigation include: Placebo (DRUG), TAK-360 (DRUG).
Who is sponsoring clinical trial NCT07633301?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.